Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn’t undermine vaccines.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...